Maker of Oxycontin to halt opioid promotion to doctors; Fewer regs could lower drug costs: White House council; Allergan picks up Australian biotech Elastagen in $95M deal; Aveo, Eusa tout promise of tivozanib combo in kidney cancer
Purdue Pharma faces sharp criticism, as well as lawsuits, for the role its marketing of prescription painkillers may have played in shaping the opioid epidemic.
The BioPharma Dive Brand Studio teamed up with Catalent to survey hundreds of executives and key stakeholders in the clinical trial space. For access to the survey results and expert insights into the future of clinical supplies, download the free report.
Buying Elastagen's tissue repair platform fits with Allergan's "bolt-on" approach to dealmaking and further expands the pharma's medical aesthetics capabilities.
Early results from a trial testing tivozanib together with Opdivo showed enough merit to further explore combo treatment — in the companies' eyes, at least.
Our mission is to provide busy execs like you with an overview of the BioPharma industry in 60 seconds. BioPharma Dive is a product of Industry Dive. View other Industry Dive publications.
This email is optimized for display on mobile phones. BioPharma Dive is a product of Industry Dive, Inc.. 1575 Eye St NW, 4th Floor, Washington, DC 20005. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to [email protected]. You can unsubscribe or change which newsletters you receive anytime. See our full privacy policy.